


# Biphasic Clinical Overview

Full energy biphasic 360 Joule technology  
Stryker's LIFEPAK® monitor/defibrillators

## Key definitions

**Monophasic waveform**  
(older, single direction energy delivery, higher peak current)

**Biphasic waveform**  
(modern, bidirectional energy delivery, less peak current)



▪ **Biphasic Truncated Exponential- BTE**

(dynamic current and duration, fixed shape)

▪ **Rectilinear Biphasic Waveform- RBW**

(dynamic current and shape, short fixed duration)

## Energy expressed in joules

(combined metric of current and voltage over time)

- **Joule** (unit of energy (J), 1 amp passing through 1 ohm for 1 sec)
- **Current** (flow of electricity measured in amps (A))
- **Voltage** (electromotive push or force measured in volts (V))
- **Duration** (interval of time measured in milliseconds)
- **Impedance** (resistance to flow of current measured in ohms)


**Clinical study** (human population)

**Experimental study** (animal population)



## Optimizing conversion rates

Biphasic research has provided direction on optimizing conversion rates for the 5-11% of cardiac arrest patients who are difficult-to-defibrillate.<sup>1,2</sup> The more efficient biphasic defibrillation waveforms still leave room to improve conversion rates.<sup>13</sup>

- No singular electrical characteristic (current, voltage or duration) of any biphasic waveform determines conversion rate.<sup>5</sup>
- The therapeutic defibrillation dose is a defined set of electrical characteristics over a defined time, measured as energy.<sup>5</sup>
- Published clinical data strongly points to an association between higher biphasic shock energy (joules) and higher conversion rates for VF/pVT and AF.<sup>1-4</sup>



## Biphasic waveforms and maximum programmed settings\*



\*Biphasic measurements testing at 90 ohms with the Stryker's LIFEPAK 15 monitor/defibrillator, ZOLL X-Series monitor/defibrillator and Philips MRx monitor/defibrillator.<sup>6</sup> Average human impedance range is approximately 70-80 ohms.<sup>6</sup>

## Clinical evidence


1. A large volume of published data now exists on biphasic defibrillation. It should be referenced when evaluating proven performance.
2. The data shows that at the same low energy biphasic shocks, the most widely used defibrillation waveforms (BTE and RBW) have the same conversion rates from 50J to 200J.<sup>8-12</sup>
3. The data also shows that higher energy biphasic waveforms are associated with higher conversion rates for VF/pVT and AF.<sup>1-4,19</sup>
4. The 2010 and 2015 AHA Guidelines state full energy biphasic 360J is safe for patients.<sup>3,7,14-16</sup> High peak current is a primary cause of myocardial injury.<sup>17</sup> Biphasic waveforms use as much as 40% less current than monophasic waveforms.

### Published clinical performance

- Early manufacturer biphasic studies were done in EP labs on non-critical, short duration VF patients. All showed high conversion rates at lower shock energies. But biphasic performance in real-world cardiac arrest patients matters more.
- The Stryker biphasic waveform (BTE) has been studied in nearly 2X as many cardiac arrest patients as all other manufacturers' biphasic waveforms combined, across a wide range of impedances.\*

### Low energy biphasic 50J to 200J: clinical equivalence

- From 50J to 200J, five clinical cardioversion studies showed that at the same low energies, biphasic waveforms had the same conversion rates.<sup>8-12</sup>
- Three studies compared the Stryker's BTE (LIFEPAK 12) and ZOLL RBW (M Series<sup>®</sup>) waveforms.<sup>8-10</sup>
- Two studies compared the Philips BTE (MRx) and ZOLL RBW (M Series and R Series<sup>®</sup>) waveforms.<sup>11,12</sup>
- For each study; **same low energies = same conversion rates**






### Full energy biphasic 360J: clinical advantage

- Clinical studies (VF and AF) show protocols with escalating energy to full energy 360J improves conversion rates for difficult-to-defibrillate patients.<sup>1-4</sup>
- No clinical (human) evidence exists showing low energy (150J to 200J) from any monitor/defibrillator provides equivalent or superior conversion rates when compared to full energy biphasic 360J.

The only randomized, triple-blinded dosing comparison showed higher conversion rate for VF/pVT when escalating to 360J vs. a fixed protocol.<sup>3</sup>

Conversion rate were lower when 200J was repeated for recurrent VF/pVT. All were eventually converted with 360J.<sup>2</sup>

Conversion rate probability increased in a subset of VF/pVT patients who received shocks at each energy dose. 360J had the highest cumulative rate.<sup>1</sup>



\*These data represent the cumulative number of cardiac arrest patients in whom the VF termination efficacy (using the established definition of "removal of VF for ≥ 5 seconds") of specific biphasic waveforms and energy levels has been reported in published papers describing either randomized or consecutive case series of OHCA or IHCA patients. Included are papers that report a VF termination rate for at least one of 1) first shocks or 2) all shocks.

## Biphasic defibrillation comparison

	LIFEPAK monitor/defibrillators and AEDs	ZOLL E Series® ZOLL M Series monitor/defibrillators	ZOLL X Series ZOLL R Series monitor/defibrillators	Philips monitor/defibrillators and AEDs
<b>Published biphasic data on cardiac arrest patients*</b>	11 studies 2,808 patients	3 studies 441 patients	0 studies 0 patients	8 studies 934 patients
<b>Max programmed setting</b>	360 Joules	200 Joules	200 Joules**	150 Joules - AED 200 Joules - ALS
<b>Biphasic waveform type</b>	BTE	RBW	RBW	BTE
<b>Biphasic waveform duration</b>	13.4 - 18.9 ms <sup>20</sup>	10 ms <sup>21</sup> (fixed)	10 ms <sup>22</sup> (fixed)	8.6 - 17 ms <sup>23</sup>

\*These data represent the cumulative number of cardiac arrest patients in whom the VF termination efficacy (using the established definition of "removal of VF for  $\geq 5$  seconds") of specific biphasic waveforms and energy levels has been reported in published papers describing either randomized or consecutive case series of OHCA or IHCA patients. Included are papers that report a VF termination rate for at least one of 1) first shocks or 2) all shocks. Based on information available in the published literature as of March 2018.


\*\*May deliver more energy than the E Series, M Series and ZOLL AEDs.<sup>21,22</sup> This is less than the maximum energy delivered in LIFEPAK monitor/defibrillators and LIFEPAK AEDs.

## Clinical strategies to improve conversion rates

The Critical Mass Theory is a meaningful conceptualization that can help clinicians improve conversion rates.<sup>5</sup> The goal is to depolarize as much of the myocardial tissue as possible at once, placing it into a repolarized, refractory state unable to re-propagate the electrical misfires that cause VF/pVT. Two controllable factors can significantly impact this complex biological interaction.


### 1. Optimize the size of the defibrillation field

Higher energy (J) can increase a shock's myocardial coverage while less energy likely covers less. Data supports escalating to 360J as a mechanism to maximize conversion rates.<sup>1-4,18</sup>



### 2. Optimize the vector of the defibrillation field

Suboptimal pad placements can also lower conversion rates. Escalating to 360J can compensate for these variations.<sup>19</sup>



## Closing points

- Science recognizes that no individual characteristic of a well-designed biphasic waveform determines conversion rate. The combined total of a shock's electrical characteristics (energy expressed in joules), determines conversion rate.
- The data shows that at the same low energy biphasic shocks, the most widely used defibrillation waveforms (BTE and RBW) have the same conversion rates from 50J to 200J.
- Published clinical data demonstrate protocols with escalating energy to 360J improves conversion rates for difficult-to-defibrillate VF and AF patients.
- No commercially available defibrillator on the market offers equivalent strength to full energy biphasic (360J) offered by Stryker's LIFEPAK defibrillators for both AED and manual defibrillation.

## References

1. Walker G, Koster R, Sun C, et al. Defibrillation probability and impedance change between shocks during resuscitation from out-of-hospital cardiac arrest. *Resuscitation*. 2009;80:773-777.
2. Koster R, Walker R, Chapman F. Recurrent ventricular fibrillation during advanced life support care of patients with prehospital cardiac arrest. *Resuscitation*. 2008;78:252-257.
3. Stiell I, Walker R, Nesbitt L, et al. Biphasic trial a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest. *Circulation*. 2007;115:1511-1517.
4. Khaykin Y, Newman D, Kowalewski M, et al. Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation: a randomized clinical trial. *Journal of Cardiovascular Electrophysiology*. 2003;8(14):868-872.
5. Tacker W.A. DEFIBRILLATION OF THE HEART. October. 1993.
6. Physio-Control Internal Testing of the LIFEPAK 15 Defibrillator Monitor, Philips MRx Defibrillator Monitor, ZOLL X-Series Defibrillator Monitor. 2017. 3333950 Competitor Waveform Recordings, Attachment A
7. Link M, Atkins D, Passman R, et al. Part 6: Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122:S706-719.
8. Kim M, Kim S, Park D, et al. Comparison of rectilinear biphasic waveform energy versus truncated exponential biphasic waveform energy for transthoracic cardioversion of atrial fibrillation. *The American Journal of Cardiology*. 2004;11(94):1438-1439.
9. Neal S, Ngarmukos T, Lessard D, et al. Comparison of the efficacy and safety of two biphasic defibrillator waveforms for the conversion of atrial fibrillation to sinus rhythm. *The American Journal of Cardiology*. 2003;92:810-814.
10. Alatawi F, Gurevitz O, White R, et al. Prospective, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic biphasic cardioversion of atrial fibrillation. *The Heart Rhythm Society*. 2005;4(2):382-387.
11. Deakin C, Connelly S, Wharton R, et al. A comparison of rectilinear and truncated exponential biphasic waveforms in elective cardioversion of atrial fibrillation: a prospective randomized controlled trial. *Resuscitation*. 2013;3(84):286-291.
12. Santomauro M, Borrelli A, Ottaviano L, et al. Cardioversione elettrica esterna in pazienti con fibrillazione atriale: confronto fra tre differenti forme di onda. *Ital Heart J Suppl*. 2004;1(5) 36-43.
13. Stothert J, Hatcher T, Gupton C, et al. Rectilinear biphasic waveform defibrillation of out-of-hospital cardiac arrest. *Prehospital Emergency Care*. 2004; 8 (4):388-392
14. Link M, Berkow L, Kudenchuk P, et al. Part 7: Adult Advanced Cardiovascular Life Support 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular. *Circulation*. 2015;132[suppl 2]:S448.
15. Higgins S, Herre J, Epstein A, et al. A comparison of biphasic and monophasic shocks for external defibrillation. *Prehosp Emerg Care*. 2000;4:305-313.
16. Martens P, Russell J, Wolcke B, et al. Optimal Response to Cardiac Arrest study: defibrillation waveform effects. *Resuscitation*. 2001;49:233-243.
17. Tsai M, Tang W, Castillo C, et al. Individual effect of components of defibrillation waveform on the contractile function and intracellular calcium dynamics of cardiomyocytes. *Crit Care Med*. 2009;37:1-8.
18. Walker G, Melnick S, Chapman F, et al. Comparison of six clinically used external defibrillators in swine. *Resuscitation*. 2003;57:73-83.
19. Esibov A, Chapman F, Melnick S, et al. Minor variations in electrode pad placement impact defibrillation success. *Prehospital Emergency Care*. 2015;1-7.
20. Physio-Control. LIFEPAK 15 Defibrillator/Monitor. Operating Instructions. Publication Date: 07/2014. PN: 3314911-003.
21. ZOLL E-Series Operators Guide. REF: 9650-121-01 Rev. T. June, 2014.
22. ZOLL X-Series Operator's Guide. REF: 9650-001355-01 Rev. P. September, 2016.
23. Physio-Control Internal Testing of the LIFEPAK 15 Defibrillator Monitor, Philips MRx Defibrillator Monitor, ZOLL X-Series Defibrillator Monitor. 2017. 3333950 Competitor Waveform Recordings, Attachment B.

**For further information, please contact Stryker at 800 442 1142 (U.S.), 800 668 8323 (Canada) or visit our website at [strykeremergencycare.com](http://strykeremergencycare.com)**

## Emergency Care

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: LIFEPAK, Stryker. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.

GDR 3336407\_C  
Copyright © 2020 Stryker

Physio-Control, Inc.  
11811 Willows Road NE  
Redmond, WA, 98052 U.S.A.  
Toll free 800 442 1142  
[strykeremergencycare.com](http://strykeremergencycare.com)

Stryker Canada  
2 Medicorum Place  
Waterdown, Ontario  
L8B 1W2  
Canada  
Toll free 800 668 8323